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Abstract: Neurofibromatosis type 1 (NF1) is a monogenic syndrome that gives rise to numerous
symptoms including cognitive impairment, skeletal abnormalities, and growth of benign nerve
sheath tumors. Nearly all NF1 patients develop cutaneous neurofibromas (cNFs), which occur on
the skin surface, whereas 40–60% of patients develop plexiform neurofibromas (pNFs), which are
deeply embedded in the peripheral nerves. Patients with pNFs have a ~10% lifetime chance of
these tumors becoming malignant peripheral nerve sheath tumors (MPNSTs). These tumors have
a severe prognosis and few treatment options other than surgery. Given the lack of therapeutic
options available to patients with these tumors, identification of druggable pathways or other key
molecular features could aid ongoing therapeutic discovery studies. In this work, we used statistical
and machine learning methods to analyze 77 NF1 tumors with genomic data to characterize key
signaling pathways that distinguish these tumors and identify candidates for drug development.
We identified subsets of latent gene expression variables that may be important in the identification
and etiology of cNFs, pNFs, other neurofibromas, and MPNSTs. Furthermore, we characterized the
association between these latent variables and genetic variants, immune deconvolution predictions,
and protein activity predictions.
Keywords: neurofibromatosis type 1; nerve sheath tumor; cancer; latent variables; machine learning;
supervised learning; transfer learning; random forest; metaVIPER; tumor deconvolution
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1. Introduction
Neurofibromatosis type 1 is a rare disease and a member of the family of RASopathies
(diseases caused by germline mutations in genes that encode components or regulators of the
Ras/mitogen-activated protein kinase (MAPK) pathway) that occurs in approximately 1 in 3000
patients worldwide and gives rise to cognitive impairment, skeletal abnormalities, and various nerve
tumors including gliomas and neurofibromas and is caused by a mutation or deletion in one NF1
allele [1–3]. Nerve sheath tumors affect more than 90% of NF1 patients, mostly in the form of cutaneous
neurofibromas (cNFs). These tumors grow at the skin surface and can range in number from 10s to 100s
of tumors in a given patient [4]. Neurofibromas that occur deeper in the body, including subcutaneous
neurofibromas or plexiform neurofibromas (pNFs), occur in 40–60% of NF1 patients and can cause
pain and disfigurement among other symptoms [1,4]. Patients with pNFs have a 10% lifetime risk
of these tumors developing into malignant peripheral nerve sheath tumors (MPNSTs) which have a
5-year survival rate of 40–50% [5,6].
The rise of high-throughput genomic and transcriptomic sequencing has enabled many advances
in understanding the molecular etiology of NF1 tumor types [7–11]. Genomic studies of NF1-derived
tumors, particularly MPNSTs, have identified key features of tumor growth that could point to potential
therapeutic avenues. For example, genomic approaches were recently used to identify the loss of
function of polycomb repressor 2 complex components EED or SUZ12 genes, alongside CDKN2A and
NF1 gene mutations as crucial co-mediators of MPNST transcriptional dysregulation, pathogenesis,
and sensitivity to bromodomain (BRD4) inhibitors [9,11]. Others using genomic approaches to explore
nerve sheath tumor biology identified MET and HGF gene amplifications in MPNSTs. Furthermore,
models of MET-amplified MPNSTs were subsequently sensitive to the MET inhibitor capmatinib [7].
Transcriptomics-focused approaches have also identified molecular features such as MEK signaling,
type 1 interferon signaling, and Aurora kinase A as putative therapeutic targets in NF1 tumors [12–14].
Taken together, these and other studies suggest that an integrative approach that combines multiple
transcriptomic and genomic datasets might be well poised to identify new therapeutic avenues in
MPNSTs and other NF1-related nerve sheath tumors.
Previous genomic profiling studies have demonstrated that many NF1 nerve sheath tumors
(MPNST being the exception) are genetically quiet [3,15–17] and lack specific signatures that are
predictive of drug response. An approach to compensate for the lack of genetic hotspots in NF1 tumors
is to focus on combinations of transcriptomic signatures that may be unique to specific tumor types. In
other tumor types, transcriptomic landscapes across cancer datasets [18,19] have shown that combining
RNA-seq data from similar diseases can identify expression profiles that correlate with prognosis [20],
predict drug response [21,22], or identify key tumor biology [23].
However, comprehensive analysis of genomic data in NF1 tumors is limited [3]. To enable a larger
landscape analysis of NF1 nerve sheath tumors, samples from different studies were collated into a
single resource as part of the NF Open Science Initiative, a collaboration between NF-related funding
agencies. This resource has been made publicly available through the NF Data Portal, which houses
high-throughput data for neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis [24].
In this work, we reprocessed and analyzed RNA-seq data from 77 NF1 nerve sheath tumor
samples to understand the biological differences that give rise to distinct tumor types in NF1 patients.
Given the low sample size compared to the large feature space of RNA-seq data, we applied a
transfer learning-inspired approach to meaningfully reduce the feature space with minimal decrease in
information content. Transfer learning techniques can leverage large well curated datasets such as
recount2 [25] to identify latent variables (LVs)—groups of genes derived from larger repositories of
gene expression datasets that exhibit common transcriptomic patterns relevant to a specific subset of
samples [26,27]. Although many of these LVs are composed of genes that map to known signatures
(i.e., documented in Kyoto Encyclopedia of Genes and Genomes (KEGG) database, and Gene Ontology
(GO) consortium database), others are uncharacterized and may allow the detection of novel and
meaningful transcriptomic patterns in NF data. As a result, reduction of gene-based expression
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data to individual latent variables can provide multiple benefits—LVs can highlight differences in
known biology in sets of samples, they can uncover previously unknown biology, and they can reduce
the impact of technical and experimental differences across multiple datasets [26]. We transferred a
machine learning model [27] trained on recount2 to assess LV expression in the NF1 nerve sheath tumor
dataset. We then used supervised machine learning with random forests [28] to isolate combinations
of such LVs to identify specific molecular signatures that may describe the underlying biology unique
to each of the tumor types: cNFs, pNFs, undefined neurofibromas (NFs), and MPNSTs. Finally, we
integrated this information with sample-matched variant data, immune cell signatures [29–31], and
protein activity predictions [32] to provide additional biological context to the most important latent
variables. This approach revealed biological patterns that underlie different NF1 nerve sheath tumor
types and candidate genes and cellular signatures associated with NF1 tumor heterogeneity.
2. Materials and Methods
2.1. Materials Implementation and Data and Code Availability
All analyses were performed using the R programming language. A comprehensive list of packages
used and their versions are available in an renv lockfile in the GitHub repository. Key packages used
include “tidyverse” [33], “PLIER” [26], “synapser” [34], “tximport” [35], “immundeconv” [35], and
“viper” [32]. All data analyzed in this article are stored on the NF Data Portal [24] (http://nfdataportal.org)
with analyses stored at http://synapse.org/nf1landscape. To recapitulate the analysis from these data,
all relevant code can be found at https://github.com/Sage-Bionetworks/NF_LandscapePaper_2019.
2.2. Sequencing Data Collection and Processing
Gene expression data were collected from four independent studies and processed via a workflow
at https://github.com/Sage-Bionetworks/rare-disease-workflows/tree/master/rna-seq-workflow to be
stored on the NF Data Portal (Table 1). Specifically, raw fastq files were downloaded from Synapse
and transcripts were quantified using the Salmon pseudo-alignment tool [36] with Gencode V29
transcriptome. Links to specific datasets and the access teams required to download them can be found
using Synapse ID syn21221980.
Table 1. Description of the gene expression datasets used in the present article.
Dataset Name Synapse Project Name Synapse Table Name Synapse Access Team





JHU Biobank [37] A Nerve Sheath Tumor Bank fromPatients with NF1 (syn4939902) Biobank RNASeq Data
JHU Biobank Data
Access
cNF Patient Data [38] Cutaneous Neurofibroma DataResource (syn4984604) cNF RNASeq Counts
CTF cNF Resource Data
Access Group
CBTTC Data [39] Children’s Brain Tumor TissueConsortium (syn20629666) CBTTC RNASeq Counts
CBTTC Data Access
Group
Genomic variant data were collected from exome-Seq [37] or whole-genome sequencing [38].
Variant call format (VCF) files were processed using “vcf2maf” (https://github.com/mskcc/vcf2maf)
according to the workflow located at https://github.com/Sage-Bionetworks/rare-disease-workflows/
tree/master/gene-variant-workflow and then uploaded to the NF Data Portal. A list of datasets and the
access teams required to download them can be found in Table 2 or syn21266269.
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2.3. Latent Variable Calculation and Selection
We analyzed transcriptomic data from NF in the context of latent variables from MultiPLIER, a
machine learning resource designed to aid in rare disease analyses [27]. Raw transcriptomic data from
NF were retrieved from the NF Data Portal, reprocessed, and stored in Synapse as described above.
Salmon output files (quant.sf) files were imported into an R session and converted to HUGO gene
names using the “tximport” [35] and “org.Hs.eg.db” [40] packages.
MultiPLIER reuses models that were trained on large public compendia. We retrieved a model [41]
that was previously trained on the recount2 RNA-seq dataset [25,42] and then used it to assess the
expression of latent variables in the pan-NF dataset. We retrieved code for this analysis from the public
repository for MultiPLIER [27] (https://github.com/greenelab/multi-plier). To project the NF data into
the MultiPLIER model, we used the GetNewDataB function. This analytical approach is described
in more detail in a machine learning training module (https://github.com/AlexsLemonade/training-
modules) produced by the Alex’s Lemonade Stand Foundation’s Childhood Cancer Data Lab under an
open source license.
In addition, to ensure orthogonality in the final set of latent variables [43], we calculated the
pairwise Pearson correlation of all latent variables by comparing the gene loadings (Figure S1),
and identified non-self-correlations greater than 0.5. We eliminated one of each of these highly
intercorrelated (Pearson correlation > 0.5) latent variables. This process resulted in a final set of 962
latent variables for further analysis. Code for our implementation of this material is available on
GitHub at https://github.com/Sage-Bionetworks/NF_LandscapePaper_2019.
We used the R function prcomp to compute the principal components for Figure 1A,C both using
genes (Figure 1A) and latent variables (Figure 1C).
2.4. Generation of Ensemble of Random Forests for Feature Selection
To select gene expression patterns of interest, we used ensembles of random forests to sufficiently
resample our modestly sized dataset. We compared random forest models built using gene expression
data as well as latent variables.
2.4.1. Algorithm Implementation
The main algorithm was implemented using the “caret” and “randomforest” packages in R [44,45].
Figure S2 outlines the steps involved in the generation of the ensemble of random forests. Briefly, the full
dataset was first split into 80% model set and 20% independent test set. The function createDataPartition
was used to create balanced splits of the data according to the tumor type. We tuned two parameters
to the random forest algorithm, mtrys, and ntrees, using an iterative approach, evaluating mtrys values
of 1 to 100 and ntrees values of 250, 500, 1000, and 2000. We selected the optimal values (mtry = 51,
ntrees = 1000) using fivefold cross-validation, using latent variables as input features. We then split the
model training set further to generate 500 samples of training data (75%) and hold-out test data (25%)
(balanced splits randomly sampled without replacement). Each of these training and test datasets were
used to train separate random forests to obtain a distribution of F1 scores and feature importance scores
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(n = 500). Given our noisy dataset with limited sample size, the distribution of feature and F1 scores
enabled estimation of confidence intervals for the feature importance as well as model performance.
2.4.2. Feature Selection
The importance of each feature was estimated using raw importance scores that measure the
change in correctly classified “class” due to random permutation of the values for the feature. To
select the top features for a specific class (i.e., tumor type), we calculated the median importance score of
each feature from the distribution of raw importance scores generated through 500 iterations of random
forests. The top 40 features were selected according to the mean decrease of the Gini index. The union
of top features from all classes was then used as a restricted feature set to train another 500 iterations of
random forests as described above. However, each new forest trained with the restricted feature-set
was tested using the independent test set to examine the performance of the model on a completely
unseen dataset. For each class, the median F1 scores of the new ensemble of forests were compared to
the previous ensemble of random forests. Improvement of median F1 scores for each class in the final
ensemble of random forests compared to the earlier one suggested that the selected features from each
class were sufficiently informative for their classification. This subset of features was then selected for
downstream analyses.
2.5. Immune Subtype Prediction
To understand the relative immune infiltration across the nerve sheath tumors studied, we used
two tumor deconvolution methods: CIBERSORT and MCP-counter, as implemented through the
“immunedeconv” R package [29–31]. Analysis is located at https://github.com/Sage-Bionetworks/NF_
LandscapePaper_2019 and results were uploaded to a Synapse table (syn21177277) that includes the
tumor-specific immune cell scores for both algorithms as well as associated tumor metadata.
2.6. MetaVIPER
We applied the metaVIPER algorithm [32] to infer protein regulatory activity based on the
tissue gene expression profiles. This algorithm builds transcriptional regulatory networks across the
cancer genome atlas (TCGA) [32,46] and uses these to build consensus predictions for a sample of
other origin. The resulting analysis is uploaded to Synapse and stored at syn21259610 along with
tumor-specific metadata.
2.7. VIPER Correlation Clustering and Drug Enrichment Analysis
A heatmap and subclusters of latent variables that had similar VIPER protein predictions were
generated using the “pheatmap” R package [47]. We observed five clear clusters of latent variables;
these clusters were defined using the R cutree function to isolate the five clusters and their contents.
We then calculated the mean correlation of each VIPER protein within each cluster to generate a
consensus protein activity prediction for each latent variable cluster. Then, we used gene set enrichment
analysis (via the “clusterProfiler” R package [48]) to assess whether drug targets were enriched in
the five consensus protein lists. Drug-wise target lists were obtained from the Drug Target Explorer
database [49]. Significant enrichment was defined as any positively enriched drug (i.e., a VIPER protein
positively correlated with the latent variable cluster) with a Benjamini–Hochberg corrected p-value <
0.05. Results were plotted using “ggplot” and “enrichplot” packages [33,50]. To plot the LV cluster
expression by tumor type, we calculated the mean expression of all latent variables for each cluster
and for each tumor sample.
3. Results
We collected mRNA sequencing, exome sequencing, and whole genome sequencing data from
previously published or publicly available resources as depicted in Table 3. We applied a combination
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of methods to identify biological mechanisms of interest in the samples that had patient-derived
transcriptomic data. Briefly, we employed a transfer learning-inspired approach to group transcripts
into latent variables (LVs), and then selected the LVs that best separate out tumors by tumor type using
an ensemble of random forest models. We evaluated the selected LVs for patterns of immune cell gene
expression, protein activity, and gene variants.
Table 3. Summary of individuals and samples for the NF1 nerve sheath tumors used in this study.
All samples have gene expression data and a subset have genomic data derived from whole-exome
sequencing or whole genome sequencing. Some neurofibromas did not have more specific pathologic
subtyping information available, and therefore were classified as “undefined neurofibromas” or NFs.
Tumor Type Individuals Samples # with Genomic Variant Data
Cutaneous Neurofibroma (cNF) 11 33 23
MPNST 13 13 1
Undefined Neurofibroma (NF) 12 12 11
Plexiform Neurofibroma (pNF) 19 19 5
3.1. Pan-NF Transcriptomic Analysis Identified Most Variable Latent Variables in NF1
To measure the diversity of the nerve sheath tumors at the transcriptomic level, we re-processed
RNA-seq data from three published datasets [37–39] and one unpublished dataset. Despite having
four types of nerve sheath tumors (cNFs, pNFs, NFs, and MPNSTs) across four datasets, we observed
confounding batch effects (Figure 1A) as some tumor types (e.g., cNF and NF) were derived from
separate studies. These batch effects, together with a lack of transcriptomic data from normal tissue
from NF1 patients, precluded us from carrying out any meaningful differential gene expression analysis
and motivated us to seek alternate approaches to pathway identification.
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Figure 1. Transfer learning reduced dimensionality and added additional context to gene expression
datasets. (A) Principal components analysis (PCA) of gene expressi data indicated that c unts-level
data may have been batch confounded. (B) The relative distributions of latent variable expression
across the four tumor types using a density plot indicated that the majority of latent variables (LVs)
had an expression value near 0 and that the four tum r t pes had similar latent variable expression
distributions. (C) PCA of LVs indicated ha batch effe , although reduced, may still have existed in
the LV data (D) A look at the 5% most variable LVs across the cohort of gene expression data indicated
that the latent variables represented a wide swath of biological processes, as well as some LVs that had
no clear association to a defined biological pathway.
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To reduce the dimensionality of the RNA-seq data and increase the biological interpretability, we
applied MultiPLIER, a transfer learning approach trained on the recount2 dataset, an independent
dataset comprising thousands of gene expression experiments. This analysis quantified the expression
of 962 latent variables (LVs) in all 77 samples using their gene expression data (Figure 1B, Figure S1,
Table S1). We anticipated that as long as technical confounders in our dataset were independent of
the technical confounders in the recount2 dataset, we would be able to find some latent variables that
were independent of batch effects. We observed that expression of the latent variables was uniformly
distributed across the four tumor types (Figure 1B). Furthermore, principal components analysis
suggested that this method reduced the size of the previously observed batch effects (Figure 1A,C) as
the within-cluster distances were significantly reduced (Figure S3, p-value = 2.1 × 10−182, Wilcoxon test).
We then sought to identify which LVs characterize the differences between individual tumors. To
find these, we examined the LVs with the 5% largest standard deviation across all LVs. Many of the
resulting latent variables (Figure 1D) were found to be associated with known biological mechanisms
including metabolic, immune, and transcription-related signatures. However, this analysis did not
explore the association between tumor types and latent variables. Therefore, we performed additional
analyses to (1) identify the gene expression features that best define each tumor type and (2) elucidate
the biological mechanisms underlying the most important latent variables.
3.2. Ensemble of Random Forests Identified Latent Variables That Robustly Describe Individual Tumor Types
To identify these expression features, we used random forest models, an approach that is known
for its ability to characterize complex decision spaces better than basic clustering approaches [28].
Random forests achieve this by building decision trees that account for both the values of the features
and conditional logic at each “branch” of the tree. Although random forest models are generally used
to classify samples, in this study we leveraged the capacity of random forest models to identify features
in the data that provide meaningful information. Therefore, in this study, our focus was to identify
important features rather than building the most accurate classifier.
We generated a random forest using NF-specific latent variable scores (Table S1) as described in
the Materials and Methods section and depicted in Figure S2. Given the limited number of samples in
our dataset, particularly for some tumor types, we anticipated high variability in the performance
of our supervised learning model. To obtain a distribution of model performance, we generated 500
training sets (using stratified sampling from the full dataset without replacement), each training their
own random forest. We used the distribution of model accuracy measurements and feature importance
scores from these forests to estimate overall model performance and feature importance (Figure 2A).
We then compared the class-specific accuracy measurements (median accuracy scores: cNF = 0.97,
MPNST = 0.67, NF = 0.67, pNF = 0.57) (Figure 2A) to those from forests built with only the top 40
LVs from each class (a total of 98 LVs) from the first forest ensemble. Using the top 40 set of LVs, we
were able to improve model performance for each tumor type on an independent test set (median
accuracy scores: cNF = 1.00, MPNST = 0.86, NF = 0.86, pNF = 0.75) (Figure 2B). For each tumor type,
reducing the feature set to these 98 LVs significantly improved the median accuracy scores for the
models (Mood’s median test p-values: cNF < 2.2 × 10−16, MPNST = 3.789 × 10−11, NF = 7.297 × 10−09,
pNF < 2.2 × 10−16). This suggested that the 98 selected LVs with high importance scores for each tumor
type were sufficient for characterizing the specific tumor types (Figure 2C).
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for downstream analysis. For example, one of the four latent variables predictive of all four tumor
types was enriched in genes associated with neuronal signaling (Figure 3Bii), suggesting that this
measurement is required for the model to distinguish various tumors as the presence of neuronal tissue
likely varies across tumor types. Other functionally enriched latent variables, such as those depicted in
Figure 3Bi,iii, implicate other biological pathways in tumor growth. However, many of the selected
latent variables still remain uncharacterized (few examples shown in Figure 3Ci–iii).
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variants in cNFs and two genes with variants in one neurofibroma sample. An example of how these 
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Figure 3. Selected latent variables (LVs) represented gene combinations unique to each tumor type.
(A) Venn diagram showing the distribution of the top 40 LVs from each tumor type. (B,C) Total
values of the LVs as measured by multiPLIER across samples are represented in the dot-plots, where
color of the dots represents the tumor type (“Class” label colors described in the lower left). Loading
values for the top 10 genes for each LV are represented in bar-plots below. The higher the loading, the
greater impact that the gene expression had on the total multiPLIER value. (B,i–iii) Genes constituting
the latent variables associated with known cell signaling pathways. (C,i–iii) Genes constituting the
uncharacterized latent variables.
3.4. LV Scores May Be Attributed to Specific Gene Variants for Specific Tumor Types
To characterize the 73 LVs with no associated pathway information, we focused on the 40 samples
from our dataset (Table 3) that had matched gene variant data (WGS or exome-Seq) to assess if there
were any genes that, when mutated, caused a significant change in LV expression. The results of this
calculation are found in Table S2.
We identified 22 latent variables that were significantly (Benjamini–Hochberg adjusted p < 0.01)
associated with single gene variants (Table S3). These latent variables, along with the genes whose
variants are associated with altered expression, are depicted in Figure 4A. This approach failed to
identify any genes that were mutated across multiple tumor types. In the list of genes in which variants
were associated with changes in latent variable expression, we identified nine genes with variants in
Genes 2020, 11, 226 10 of 19
cNFs and two genes with variants in one neurofibroma sample. An example of how these variants
are associated with the expression of a latent variable is depicted in Figure 4B. Mutations in the nine
cNF-variant genes are associated with lower expression of LV 851. Because most of these variants
occur in cNF samples but not in the other tumor types, it is not surprising that this latent variable is
down-regulated across all cNFs (Figure 4C). Figure 4D shows that the MAP1B gene, which has been
reported to play a role in glioblastoma [51] but has not been studied in NF1-linked tumors, is a major
contributor towards this LV.
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Figure 4. Some genes significantly distinguished expression of latent variables. (A) Latent variables
(y-axis) whose values are significantly altered by mutations in specific genes. (B) MultiPLIER value of
LV 851 across tumor samples. (C) MultiPLIER value of LV 851 across all samples. (D) Loading values
of the top 20 genes that comprise LV 851.
3.5. Selected Latent Variables Represented Specific Immune Cell Types in the Tumor Microenvironment
Given the limited representation of different NF1 tumor types in our genomic variant dataset,
we used alternate gene expression metrics to assess the biological underpinnings of the 73
uncharacterized latent variables. We performed tumor immune cell deconvolution analysis [29–31] to
identify potential immune infiltration signatures present in the individual tumors using CIBERSORT
and MCP-counter (Table S4). Specifically, CIBERSORT deconvolution indicated the presence of
activated mast cells and M2 macrophages in all tumor types (Figure 5A). The analysis further suggested
that all of the tumors have a population of resting CD4+ memory T cells. The results from MCP-counter,
depicted in Figure 5B, show a complementary view of the tumor cell types due to the slightly different
categorization of cell types. Specifically, we found the presence of cancer-associated fibroblasts across
all tumors that were not captured in CIBERSORT.
We then used the immune scores from CIBERSORT and MCP-counter to probe some of the latent
variables selected by the random forest model to better understand their role in NF1 tumor biology.
We first searched for tumor deconvolution scores that were correlated with latent variable expression
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across all tumors. Figure 5C,E show specific LVs where the immune scores of the samples highly
correlated with a predicted immune cell type. LV 546, for example (Figure 5C), was found to have
a high correlation of activated mast cells in cNF samples. Figure 5E shows that LV 540 has immune
scores strongly correlated with T cells in all NF1 tumor types. Complete results of immune scores
across all tumors can be found in Table S4. Together, these results suggest that the selected LVs capture
signatures from the tumor microenvironment in NF1 samples.
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3.6. Selected Latent Variables Captured Protein Regulatory Networks in NF1 Tumors
Of the 98 latent variables selected by the random forest, 55 could not be characterized via
enrichment of the gene loadings (Figure 3), mutational patterns (Figure 4), or immune subtypes
(Figure 5). To characterize them, we applied the metaVIPER algorithm [32] to identify specific protein
activity measurements that correlated with latent variable expression. This algorithm leverages
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previously published regulatory network information [52] to infer protein activity in each sample to
assign numerical scores of activity across 6168 proteins for each of the 77 samples (Table S5). We then
measured the correlation of these scores and latent variable scores (Table S6, Figure 6A) to identify
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Figure 6. Integration of protein activity information with LVs can identify candidate drug targets for
different NF1 tumor types. (A) A heatmap of correlation scores of known proteins with regulatory
networks (or regulons) that are represented in the characterized and uncharacterized LVs selected above.
The green bar across the top depicts how many protein activity scores had a Spearman correlation
greater than 0.65. (B) Clustering of the LV-correlated VIPER proteins highlighted five clusters of
latent variables with similar VIPER protein predictions, suggesting that these five clusters may have
functional overlap. (C) Mean LV expression within the clusters highlighted differential expression
within the clusters across tumor types. Tumor type is indicated by colors on the right. (D) Drug set
enrichment analysis of the average VIPER protein correlation of cluster 2 identified some drugs and
preclinical molecules that are enriched with targets in this cluster.
As seen in previous work [43], we observed that multiple latent variables exhibit similar correlation
patterns with active proteins (Figure 6A). We clustered the correlation scores to see if we could group
the latent variables with similar protein activity predictions (Figure 6B). In clustering the latent
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variable–protein activity scores, we observed five distinct clusters of latent variables with similar
predicted protein activities (Figure 6B). Aggregation of each cluster of latent variables (mean expression
within each cluster) demonstrated that these functional clusters were differentially expressed in the
different NF1 tumor types (Figure 6C).
We then assessed the druggability of each of these five clusters by taking the average correlation of
each protein within the cluster and performing gene set enrichment analysis against a database of small
molecules with known biological targets [49]. This enabled the identification of drugs and drug-like
compounds that are significantly enriched for targets in each cluster (Table S7). For example, cluster 2,
which is expressed in pNF, NF, and MPNST more than it is expressed in cNF, has correlated VIPER
proteins that are enriched for both clinically approved drugs (dovitinib) and drug-like small molecules
(Figure 6D). Furthermore, we found that cluster 3 was enriched for compounds that affect cell cycle
progression (e.g., dinaciclib, abemaciclib), whereas clusters 1 and 5 were enriched for compounds such
as CUDC-101 (7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide) and
analogs that inhibit histone deacetylases (Figure S4).
4. Discussion
NF1 is the most common of all neurofibromatosis syndromes and is caused by the loss of function
of NF1 gene (a known tumor suppressor) due to mutation or deletion. However, NF1 patients show a
great deal of phenotypic heterogeneity [1]. Identification of candidate cellular signaling pathways
that differentiate between various tumor types is key for understanding the biology underlying such
phenotypic diversity, as well as predicting progression of tumor types towards malignancy. In this
study, we integrated various in silico resources and analytical techniques to identify candidate genes or
pathways unique to different tumor types in an attempt to generate testable hypotheses. By capturing
complex gene expression patterns using latent variables (LVs), we identified combinations of LVs that
were important to classify tumor types. An ensemble of random forests was then used to select 98
latent variables that were important and sufficient for identifying and classifying the various tumor
types with reasonably high accuracy (Figure 2). The selected LVs were then subjected to downstream
analyses using different data modalities to gain insight into the composition and relevance of the
LVs in the context of NF1 (Figures 3–6). The selected latent variables that correlated with known
pathways using tumor deconvolution methods confirmed the presence of previously described tumor
microenvironment components. Investigation into previously uncharacterized LVs in the context of
NF1 suggested the presence of (a) candidate genes for targeted experiments, (b) previously known
as well as unknown tumor microenvironment components, and (c) candidate tissue-specific protein
regulatory networks for future drug screening experiments.
To interpret the results of these analyses, we first evaluated the gene loadings of the latent variables
that were associated with one or more tumor types. We found that two of the top LVs with lower
expression in cNF but higher expression in other tumor types, LV 384 and LV 624 (Figures 3C and
6), had ties to known Schwann cells and NF1 tumor biology, as well as presence of immune cells
in the tumor microenvironment. Specifically, the EGR2 gene, one of the major components of LV
384, has been implicated in diseases associated with the myelin sheath such as Charcot–Marie–Tooth
Disease (another disease of the Schwann cell) and is thought to play a role in pathways associated
with myelination [53,54]. Indeed, clinical case studies of patients with concurrent NF1-induced
tumors and Charcot–Marie–Tooth disease have been reported in the literature, suggesting a possible
overlap in underlying biology [55–57]. Although the role of EGR2 in Schwann cell differentiation
is still under active investigation [58], EGR2-driven pathways have been found to be significantly
downregulated in Lats1/2-deficient Schwann cell-based MPNST models [59]. Similarly, the SOCS6
gene, the top component of LV 624, is known to be directly involved in immune signaling via repression
of cytokines [60] and has also been found to be a selective tumor suppressor [61]. Its upregulation in
the more malignant NF tumors (Figure 3C) suggests that this gene plays a distinct role in NF-related
tumors. Additionally, the RUNX2 gene (a major component of LV 624), has been shown to drive
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neurofibromagenesis by repression of the PMP22 gene encoded myelin protein (a Schwann cell
component) [62]. The enrichment of such genes in the selected LVs that differentiate nerve sheath
tumors from cNFs showcase the importance of Schwann cell biology in these tumors and serves as a
proof of principle for our analyses. Furthermore, EGR2 expression in immune cells has been shown
to be important for activation of M1/M2 macrophages [63] as well as regulation of CD4+ T cells [64].
As discussed later in greater detail, our downstream analysis, using all the selected LVs and tumor
deconvolution techniques, identified the enrichment of M2 macrophage and CD4+ T cell markers as
tumor microenvironment components in our samples (Figure 5A).
Alternatively, we also evaluated LVs that are uniquely associated with specific tumor types. For
example, LV 24 was found to be an important feature for classifying MPNST tumor samples but not
the other benign tumor samples (Figure 3Biii). LV 24 was found to be significantly associated with
the ∆Np63 pathway (FDR < 0.05), a pathway with implications in determining malignancy and poor
survival in various subtypes of pancreatic and squamous cell carcinomas [65]. ∆Np63 signaling in the
central nervous system is believed to play a role in neural precursor cell survival and neural stem cell
dynamics [66,67], but its role in formation or maintenance of malignant NF1 tumors such as MPNSTs is
relatively unexplored. Overall, the evidence surrounding EGR2, SOCS6, RUNX2, and ∆Np63 pathway
suggest that LV 384, LV 624, and LV 24 may be promising candidates for experimental follow-up.
Beyond looking at individual genes that comprise the latent variables, we employed orthogonal
algorithms that measured tumor immune activity and regulatory protein activity to identify
specific signatures represented by the latent variables. Tumor deconvolution methods (CIBERSORT,
MCP-counter) confirmed previously described observations such as the presence of mast cells in NF1
model systems and patient tumors [68–74]. They also suggested the presence of T cells in human
tumor samples. This has previously been described in mouse models of NF1 tumors [75]. In humans,
systemic T cell burden has been found to correlate with NF1 nerve sheath tumor progression; T cell
presence has also been observed in NF1 gliomas [10,76].
Through the metaVIPER protein regulatory activity predictions, we were able to identify putative
therapeutic candidates for further evaluation. Specifically, we found two clusters of latent variables
expressed in NF, pNF, and MPNST that had regulatory proteins enriched in targets of dovitinib and
drug-like small molecules that inhibit receptor tyrosine kinases, as well as cyclin-dependent kinase
(CDK) inhibitors such as abemaciclib or dinaciclib. These findings are consistent with previous studies
that identify CDK inhibitors as useful in models of NF1-deficient or RAS-dysregulated tumors [77–80].
Because latent variables that are correlated with histone deacetylases (HDACs) were found to be
expressed most highly in cNFs (cluster 5, Figure 6C, Figure S4C) and MPNSTs (cluster 1, Figures
4A and 6C), compounds such as CUDC-101 and analogs could be potential candidates for treating
cNF and MPNST. Indeed, HDAC inhibitors were previously found to be efficacious in in-vitro and
in-vivo models of MPNSTs [77,81]. Thus, our results further suggest that this therapeutic approach
might be feasible in both MPNSTs and cNFs. Drugs found in other clusters such as dovitinib and
lestaurinib in cluster 2, which is expressed most in MPNSTs, pNFs, and NFs (Figure 6C,D), may also
merit further study.
Although the present in-silico study brings forth various candidate genes and pathways for further
follow up, it also presents a few limitations that could be mitigated with future studies, particularly for
tumor types with limited samples such as MPNSTs and neurofibromas. Most notably, analyzing genetic
variants across tumor types failed to identify relevant variant signatures (Figure 4). This highlights the
challenges in variant analyses using samples with limited class representation and motivates our focus
on transcriptional signatures. Additional genomic and transcriptomic data from the same biobanks or
additional tumor datasets will improve our ability to identify recurrent genetic markers of tumor type.
Furthermore, additional data from tumor-adjacent normal tissue would greatly add value to additional
analyses on the basis of differential gene expression. Such differential expression analyses were not
possible within the scope of this work since these data are not currently available. Additionally, future
studies comparing genomic signatures identified here to other publicly available tumor expression
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and variant data (e.g., the Cancer Genome Atlas or the International Cancer Genome Consortium [19])
may identify genomic similarities between peripheral nerve sheath tumors and other tumors.
5. Conclusions
In conclusion, this work proposed a short list of testable hypotheses involving specific biological
signatures for NF1-deficient nerve sheath tumors. Verification of these mechanisms in in-vitro
and in-vivo models of nerve sheath tumors as well as human NF1 nerve sheath tumor tissue
needs active and extensive experimental work. Although we analyzed tumor datasets from four
different studies, the addition of other neurofibromatosis-driven tumor datasets will greatly aid
identification of commonalities or critical differences to inform therapeutic decisions across the family
of neurofibromatoses. This study, together with future work, may guide the repositioning of clinically
approved drugs in the context of NF1.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/2/226/s1.
Figure S1: (a) A density plot indicating the pairwise Pearson correlation of LVs (not including self-self-pairs).
A threshold of 0.5 was selected to eliminate non-orthogonal latent variables. Figure S2: Schematic showing
the generation of the ensemble of random forests. (A) Stratified split of original dataset into “model” set and
“independent test” set. (B) Generation of first ensemble of random forests using training set and test set generated
from the “model” set for all 962 latent variables. (i) Example density plot showing distribution of model accuracy
(F1) scores for each class. (ii) Example plot showing distribution of feature importance scores from the 500 random
forests. (C) Generation of the second ensemble of random forests using restricted feature set of only 98 latent
variables. The newly generated models were tested on the “independent test” set. (i) Example plot showing
the distribution of model accuracy scores from the second ensemble of random forests. Figure S3: A boxplot
representing the decrease in pairwise distances between all tumor samples of the same tumor type from Figure 1A
(green, based on gene clustering) to 1C (orange, based on LV clustering). Figure S4: Small molecule-target
networks showed enrichment of LV-dependent target classes. (A) Cluster 1 of LV-correlated VIPER proteins was
enriched for HDAC inhibitors. (B) Cluster 3 of LV-correlated VIPER proteins was enriched for kinase inhibitors,
particularly inhibitors of kinases responsible for cell cycle progression (CDKs). (C) Cluster 5 of LV-correlated
VIPER proteins was enriched for HDAC inhibitors. Table S1: Pan-NF1 MultiPLIER results across RNA-seq data
for 77 nerve sheath tumors. Table S2: Significance of latent variable status being correlated with gene mutation
status. Table S3: Summary of latent variables selected by random forest model and their correlated genes and
signatures. Table S4: Tumor deconvolution scores across NF1 patient samples. Table S5: metaVIPER protein
scores across all NF1 patient samples. Table S6: Spearman correlation scores of RF-selected latent variables with
metaVIPER scores. Table S7: Drug set enrichment analysis of latent variables.
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